AAMU
VYGR icon

Amundi Asset Management US’s Voyager Therapeutics VYGR Stock Holding History

Amundi Asset Management US’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-64,800
Closed -$1.27M – 1654
2018
Q2 		$1.27M Buy
+64,800
New +$1.28M ﹤0.01% 1213

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Amundi Asset Management US's VYGR Position: Q3 2018 in Review

Amundi Asset Management US sold out of Voyager Therapeutics (VYGR) in Q3 2018, closing a stake of 64,800 shares — an estimated $1.27M sold.

Amundi Asset Management US first reported a position in VYGR in Q2 2018 and held it in 1 quarter. The position peaked at $1.27M in Q2 2018. 119 funds tracked by Wall St. Rank hold VYGR as of Q3 2018.

  • Amundi Asset Management US reported no remaining Voyager Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 64,800 Voyager Therapeutics shares in Q3 2018, an estimated $1.27M.
  • Amundi Asset Management US first reported a position in Voyager Therapeutics in Q2 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Voyager Therapeutics position peaked at $1.27M in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2018.

Based on Amundi Asset Management US's 13F filing for Q3 2018, filed 14 Nov 2018.